NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE · Drug Manufacturers - Specialty & Generic · USD

Perrigo Company plc (PRGO) Stock Analysis

Perrigo Company plc (PRGO) is a Drug Manufacturers - Specialty & Generic stock listed on NYSE and quoted in US Dollar.

PRGO

$14.92

+$0.65 (+4.56%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PRGO with… →

PRGO Key Statistics

As of Sep 4, 2026
Trading
Open
$14.07
Previous Close
$14.27
Day's Range
14.07–15.00
52-Week Range
9.23–22.90
Volume
2.20M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.60
Valuation
Market Cap
$2.06B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
6.22
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.14
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.50
EPS (ttm)Profit attributable to each share over the last twelve months.
−12.29
Financials (FY)
Revenue (FY)
$4.25B−2.75%
Net Income (FY)
−$1.43B
Profit marginThe share of revenue left as profit after all costs and taxes.
−41.85%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
138.37M
1-Year Return
−32.80%
Dividend and dates
Dividend
$1.16+7.77%
Ex-Dividend Date
August 28, 2026
Earnings Date
November 4, 2026estimated
Avg Volume
3.41M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

PRGO Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+12.44%
2025−44.03%
2024−16.92%
2023−2.47%
2022−9.78%
2021−10.95%
2020−11.97%
2019+35.65%
2018−55.08%
2017+5.58%
2016 (partial year)−10.64%

As of September 4, 2026.

PRGO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$4.25B−$1.43B−33.5%
2024$4.37B−$171.80M−3.9%
2023$4.66B−$12.70M−0.3%
2022$4.45B−$140.60M−3.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$4.25B$1.49B$312.80M−$1.43B−33.5%
2024$4.37B$1.54B$311.90M−$171.80M−3.9%
2023$4.66B$1.68B$284.10M−$12.70M−0.3%
2022$4.45B$1.46B$121.40M−$140.60M−3.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

PRGO Dividend History

$0.87−21.2% vs 2024

Dividends per share, 2025 · 3 payments

YearDividends per sharePaymentsChange
2026*$0.582—
2025$0.873−21.2%
2024$1.104+1.1%
2023$1.094+5.0%
YearDividends per sharePaymentsChange
2026 (partial year)$0.582—
2025$0.873−21.2%
2024$1.104+1.1%
2023$1.094+5.0%
2022$1.044+8.3%
2021$0.964+6.7%
2020$0.904+9.8%
2019$0.824+7.9%
2018$0.764+18.8%
2017$0.644+341.4%
2016$0.151—

Most recent payment: $0.29 per share, ex-dividend May 29, 2026. Per-share amounts summed by calendar year from ex-dividend dates. Partial years are shown muted and marked with an asterisk.

PRGO Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks
MetricPRGODrug Manufacturers - Specialty & Generic medianvs median
P/S ratio0.502.300.2x the median
Profit margin−41.85%−3.14%38.7 pts below

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Perrigo Company plc (PRGO) at $2.06B. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. Headcount on file is 8,100.

The 52-week range on file runs from $9.23 to $22.90. PRGO last closed at $14.92 on September 4, 2026. That is +$0.65 (+4.56%) against the previous close. The latest close sits 61.65% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $4.25B. That is −2.75% against the prior fiscal year, when revenue was $4.37B. The same year closed with a net loss of $1.43B. Profit margin runs at −41.85%. That is 38.7 percentage points below the Drug Manufacturers - Specialty & Generic median of −3.14%. Trailing earnings per share are −12.29.

Across the 4 fiscal years on file, revenue moves from $4.45B in 2022 to $4.25B in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The forward P/E on file is 6.22. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.14. Measured against sales, the shares trade at 0.5 times revenue. On price-to-sales that is 0.2 times the Drug Manufacturers - Specialty & Generic median of 2.3. The medians here are taken across 103 Drug Manufacturers - Specialty & Generic companies that report the metric.

Beta against the wider market is reported at 0.6. Annualized volatility over the trailing 10 years is 38.37%. Over the trailing twelve months the price has returned −32.80%. Measured over 10 years, that is −14.32% a year compounded.

Growth & Income

The trailing dividend yield is 7.77%. That is 5.7 percentage points above the Drug Manufacturers - Specialty & Generic median yield of 2.06%. At the indicated rate that is $1.16 a share a year. The ex-dividend date on file is August 28, 2026. Dividends are recorded for 11 calendar years; 2026 shows 2 payments totalling $0.58 a share. The year before, 2025, totalled $0.87 a share.

So far in 2026 the price is +12.44%. Across the complete calendar years on file, 2019 returned +35.65% and 2018 returned −55.08%. Of the 9 complete calendar years on file, 2 finished higher.

Peer Comparison

Perrigo Company plc (PRGO) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Perrigo Company plc PRGO $2.06B —
Takeda Pharmaceutical Company Limited TAK $58.92B —
Teva Pharmaceutical Industries Limited TEVA $42.37B 60.6
Haleon plc HLN $42.22B 20.0

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. Perrigo Company plc has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

 TEVA

Teva Pharmaceutical Industries Limited

$42.37B

 HLN

Haleon plc

$42.22B

 ZTS

Zoetis Inc.

$31.33B

 UTHR

United Therapeutics Corporation

$20.91B

 VTRS

Viatris Inc.

$19.39B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Perrigo Company plc

Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

Visit website →